Anne-Laure Chabanon

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Paul Goepfert, Bo Fu, Anne-Laure Chabanon et al. · The Lancet Infectious Diseases · 2021 · 123 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season

Sonja Gandhi-Banga, Anne-Laure Chabanon, Cécile Eymin et al. · Human Vaccines & Immunotherapeutics · 2019 · 15 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season

Anne-Laure Chabanon, Sophie Wagué, Annick Moureau et al. · BMC Public Health · 2021 · 15 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season

Laurence Serradell, Sophie Wagué, Annick Moureau et al. · Human Vaccines & Immunotherapeutics · 2020 · 11 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17